You are here
Class I Recall of Duragesic Initiated
Janssen Pharmaceutica and FDA notified healthcare professionals of a Class I recall of DURAGESIC 75 mcg/h. Only Control Number 0327192 (expiration
October 2005) is subject to this recall. A potential seal breach on one edge may allow drug to leak from the patch and could result in an increased
absorption of the opioid component, fentanyl, leading to increased drug
effect, including nausea, sedation, drowsiness, or potentially life
threatening complications. Conversely, if the hydrogel contents leak out of
the patch, there may not be adequate medication to treat the patients' pain.
In an opioid tolerant patient, this may lead to withdrawal symptoms, which include sweating, sleeplessness and abdominal discomfort.
Read the MedWatch 2004 safety summary, including links to the Recall Notice, Janssen Patient and Caregiver Information, and product photos, at: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/default.htm
Source: The FDA Safety Information and Adverse Event Reporting Program
More Headlines
Liver Fluke Infestation Affects Almost 2.5 Million People Globally
Policy Could Be Life-Changing for People With Spinal Cord Injury
Test Determines Severity of Pain, Helps Physicians Select Best Options
Intratumoral Injection Stimulates Immune Activation
65,000+ New Diagnoses in U.S. Expected in 2019
Diabetes and Cancer Patients Could Soon Avoid Injections
Early Cancer Development May Begin in Just 30 Minutes
New Administration Option for Patients
New Treatment Option for Patients with aTTP